KR102316282B1 - 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 - Google Patents

올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 Download PDF

Info

Publication number
KR102316282B1
KR102316282B1 KR1020167029996A KR20167029996A KR102316282B1 KR 102316282 B1 KR102316282 B1 KR 102316282B1 KR 1020167029996 A KR1020167029996 A KR 1020167029996A KR 20167029996 A KR20167029996 A KR 20167029996A KR 102316282 B1 KR102316282 B1 KR 102316282B1
Authority
KR
South Korea
Prior art keywords
protected
compound
substituted
group
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167029996A
Other languages
English (en)
Korean (ko)
Other versions
KR20160147768A (ko
Inventor
프렘찬드란 에이치. 라미야
Original Assignee
제론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제론 코포레이션 filed Critical 제론 코포레이션
Priority to KR1020217033531A priority Critical patent/KR102707216B1/ko
Publication of KR20160147768A publication Critical patent/KR20160147768A/ko
Application granted granted Critical
Publication of KR102316282B1 publication Critical patent/KR102316282B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167029996A 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 Active KR102316282B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217033531A KR102707216B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US61/987,396 2014-05-01
US201562151909P 2015-04-23 2015-04-23
US62/151,909 2015-04-23
PCT/US2015/028327 WO2015168310A1 (en) 2014-05-01 2015-04-29 Oligonucleotide compositions and methods of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033531A Division KR102707216B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Publications (2)

Publication Number Publication Date
KR20160147768A KR20160147768A (ko) 2016-12-23
KR102316282B1 true KR102316282B1 (ko) 2021-10-25

Family

ID=54359301

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217033531A Active KR102707216B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020167029996A Active KR102316282B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020237018801A Ceased KR20230088509A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020247031813A Pending KR20240144488A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020217033531A Active KR102707216B1 (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237018801A Ceased KR20230088509A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법
KR1020247031813A Pending KR20240144488A (ko) 2014-05-01 2015-04-29 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법

Country Status (33)

Country Link
US (6) US9796747B2 (enExample)
EP (2) EP3137479B1 (enExample)
JP (6) JP7040892B2 (enExample)
KR (4) KR102707216B1 (enExample)
CN (3) CN117357548A (enExample)
AP (1) AP2016009489A0 (enExample)
AU (3) AU2015253158B2 (enExample)
BR (1) BR112016025196B1 (enExample)
CL (4) CL2016002749A1 (enExample)
DK (1) DK3137479T5 (enExample)
EA (1) EA034882B9 (enExample)
ES (1) ES2963740T3 (enExample)
FI (1) FI3137479T3 (enExample)
HR (1) HRP20231505T1 (enExample)
HU (1) HUE064289T2 (enExample)
IL (2) IL248044B (enExample)
JO (2) JOP20200257A1 (enExample)
LT (1) LT3137479T (enExample)
MA (1) MA63525B1 (enExample)
MX (2) MX382233B (enExample)
MY (2) MY196927A (enExample)
PE (1) PE20170147A1 (enExample)
PH (1) PH12016502080A1 (enExample)
PL (1) PL3137479T3 (enExample)
PT (1) PT3137479T (enExample)
RS (1) RS64860B1 (enExample)
SG (2) SG11201608226YA (enExample)
SI (1) SI3137479T1 (enExample)
SM (1) SMT202300405T1 (enExample)
TW (2) TWI709406B (enExample)
UA (1) UA126108C2 (enExample)
WO (1) WO2015168310A1 (enExample)
ZA (2) ZA201606624B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571601C (en) 2004-07-02 2013-01-08 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
PE20171785A1 (es) * 2015-04-23 2017-12-27 Geron Corp Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes
SMT202100701T1 (it) * 2017-07-10 2022-01-10 Geron Corp Processo migliorato per preparare imetelstat
WO2021086754A1 (en) 2019-10-28 2021-05-06 Geron Corporation Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same
ES3013623T3 (en) * 2019-10-28 2025-04-14 Geron Corp Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same
US20240391945A1 (en) 2020-01-08 2024-11-28 Nitto Denko Corporation Nucleic acid synthesis method using segment-type amidite
KR20250008345A (ko) 2023-07-07 2025-01-14 주식회사 엘지에너지솔루션 체결기구 및 체결기구를 포함하는 전지팩

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037691A1 (en) 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
WO2001018015A1 (en) * 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DK0462145T3 (da) 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO1991014696A1 (en) 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
JP4281926B2 (ja) 1993-10-18 2009-06-17 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ ニューロンの生き残りを増加させる方法およびそれに有用な薬剤
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
WO1995025814A1 (en) 1994-03-18 1995-09-28 Lynx Therapeutics, Inc. Oligonucleotide n3'→p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
DK0778842T3 (da) 1994-07-07 2006-03-20 Geron Corp Mammal telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
EP0790965A1 (en) 1994-11-07 1997-08-27 HYBRIDON, Inc. Synthesis of ?35 s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
EP1379689B1 (en) * 2001-03-23 2012-09-26 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
BRPI0414222B8 (pt) 2003-09-09 2021-05-25 Geron Corp compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados
CA2571601C (en) 2004-07-02 2013-01-08 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
CA2584984A1 (en) * 2004-10-18 2006-04-27 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
EP2101789B1 (en) 2006-10-30 2014-12-31 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037691A1 (en) 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
WO2001018015A1 (en) * 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
JP2009046483A (ja) * 1999-09-10 2009-03-05 Geron Corp オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用

Also Published As

Publication number Publication date
PE20170147A1 (es) 2017-04-12
JP7040892B2 (ja) 2022-03-23
AU2015253158A1 (en) 2016-10-20
US20180016293A1 (en) 2018-01-18
AU2022203273A1 (en) 2022-06-02
TW201622732A (zh) 2016-07-01
JP2021182946A (ja) 2021-12-02
IL248044A0 (en) 2016-11-30
LT3137479T (lt) 2023-10-10
CN117357548A (zh) 2024-01-09
KR102707216B1 (ko) 2024-09-19
RS64860B1 (sr) 2023-12-29
US20220306676A1 (en) 2022-09-29
US20240150391A1 (en) 2024-05-09
AU2020201707A1 (en) 2020-03-26
PT3137479T (pt) 2023-11-30
CL2018001213A1 (es) 2018-08-03
AU2015253158B2 (en) 2019-12-12
NZ763996A (en) 2021-03-26
MX2021004932A (es) 2021-08-16
IL248044B (en) 2019-08-29
TWI709406B (zh) 2020-11-11
BR112016025196A2 (pt) 2017-12-12
ES2963740T3 (es) 2024-04-01
CN106459134B (zh) 2020-02-18
PL3137479T3 (pl) 2024-02-26
TW202017574A (zh) 2020-05-16
EP3137479A1 (en) 2017-03-08
CN106459134A (zh) 2017-02-22
CN111228288A (zh) 2020-06-05
EP4286519A3 (en) 2024-02-28
US20250011359A1 (en) 2025-01-09
WO2015168310A1 (en) 2015-11-05
CA2943888A1 (en) 2015-11-05
ZA201606624B (en) 2020-12-23
ZA202005857B (en) 2024-01-31
IL268570B (en) 2021-10-31
DK3137479T5 (da) 2024-10-14
FI3137479T3 (fi) 2023-11-28
BR112016025196B1 (pt) 2022-08-02
EA201691786A1 (ru) 2017-04-28
CN111228288B (zh) 2023-10-20
CL2018001212A1 (es) 2018-08-03
EA034882B9 (ru) 2020-07-13
SI3137479T1 (sl) 2023-11-30
MA63525B1 (fr) 2025-02-28
JP7736489B2 (ja) 2025-09-09
AU2020201707B2 (en) 2022-02-17
KR20210130822A (ko) 2021-11-01
US20180016294A1 (en) 2018-01-18
SMT202300405T1 (it) 2024-01-10
CL2016002749A1 (es) 2017-04-28
SG11201608226YA (en) 2016-10-28
KR20230088509A (ko) 2023-06-19
AP2016009489A0 (en) 2016-10-31
HUE064289T2 (hu) 2024-02-28
KR20240144488A (ko) 2024-10-02
MY178617A (en) 2020-10-19
TWI712413B (zh) 2020-12-11
EA034882B1 (ru) 2020-04-01
MX2016014178A (es) 2017-05-04
US9796747B2 (en) 2017-10-24
JP7308309B2 (ja) 2023-07-13
US20150337314A1 (en) 2015-11-26
JP2018131453A (ja) 2018-08-23
UA126108C2 (uk) 2022-08-17
PH12016502080A1 (en) 2017-01-09
US11299511B2 (en) 2022-04-12
JO3767B1 (ar) 2021-01-31
HRP20231505T1 (hr) 2024-03-01
JP2017514479A (ja) 2017-06-08
SG10201911086XA (en) 2020-01-30
MY196927A (en) 2023-05-11
US11739114B2 (en) 2023-08-29
JP2023073510A (ja) 2023-05-25
EP3137479B1 (en) 2023-08-30
JP2020050670A (ja) 2020-04-02
EP3137479A4 (en) 2018-02-07
MX382233B (es) 2025-03-13
MA63525A1 (fr) 2024-09-30
DK3137479T3 (da) 2023-11-20
NZ724764A (en) 2021-02-26
CL2022000202A1 (es) 2023-02-10
US10392418B2 (en) 2019-08-27
KR20160147768A (ko) 2016-12-23
JP2022044679A (ja) 2022-03-17
EP4286519A2 (en) 2023-12-06
JOP20200257A1 (ar) 2017-06-16
IL268570A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
JP7736489B2 (ja) オリゴヌクレオチド組成物及びその作製方法
HK40104434A (en) Oligonucleotide compositions and methods of making the same
CA2943888C (en) Oligonucleotide compositions and methods of making the same
HK40030910A (en) Oligonucleotide compositions and methods of making the same
HK1231885B (en) Oligonucleotide compositions and methods of making the same
HK1231885A1 (en) Oligonucleotide compositions and methods of making the same
OA18106A (en) Oligonucleotide compositions and methods of making the same
EA044343B1 (ru) Неочищенная композиция полинуклеотидного соединения
OA19860A (en) Oligonucleotide compositions and methods of making the same.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5